Inclusion Criteria:  Male or nonpregnant female patients >18 years of age. Has a clinical diagnosis of Retinal Vein Occlusion (RVO) in the study eye. Best-Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score ≥ 20 (20/400 Snellen equivalent), and ≤75 in the study eye (20/32 Snellen equivalent). Central Subfield Thickness (CST) ≥310 microns measured by Spectral Domain Optical Coherence Tomography (SD-OCT) in the study eye.  Exclusion Criteria:  Intravitreal (IVT) injection of anti-VEGF: Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA/Roche, Basel, Switzerland) or ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA) within 1 month and aflibercept (Eylea®; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, and Bayer HealthCare Pharmaceuticals, Berlin, Germany) within 2 months in the study eye. Intraocular or periocular corticosteroid injection within 3 months, dexamethasone implant (Ozurdex, Allergan, Dublin, Ireland) within 6 months, Retisert (Bausch and Lomb, Bridge water, NJ) within 1 year, or fluocinolone acetonide implant (Iluvien, Alimera Sciences, Alpharetta, GA) within 3 years in the study eye. Macular laser photocoagulation treatment in the study eye. Topical ophthalmic nonsteroidal anti-inflammatory drugs in the study eye within a month. Any significant media opacity that could hinder the evaluation of the retina or ocular condition causing decreased vision other than RVO. IOP >22 mm Hg, or history of steroid-induced ocular hypertension; uncontrolled glaucoma. Past vitreoretinal or glaucoma surgery in the study eye. Uncontrolled systemic disease that could hinder follow-up, immunodeficiency, or any other systemic contraindication for steroids.